{"filing":{"accession_number":"0001437749-26-026771","cik":"0001053691","ticker":"CRVO","company_name":"CervoMed Inc.","form":"8-K","filing_date":"2026-08-10","report_date":"2026-08-10","primary_document":"crvo20260810_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1053691/000143774926026771/crvo20260810_8k.htm"},"events":[{"id":26549,"run_id":24132,"accession_number":"0001437749-26-026771","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"CervoMed issued a press release on August 10, 2026, announcing financial results for the quarter ended June 30, 2026, including cash position ($24.9 million), R\u0026D expenses ($4.3 million), G\u0026A expenses ($2.4 million), and net loss ($6.6 million). The filing explicitly states this is Item 2.02 disclosure with the press release attached as Exhibit 99.1, which is the standard format for earnings releases. The disclosure includes both financial results and material corporate updates (equity financings of $20.5 million, clinical trial progress, regulatory designations).","company_name":"CervoMed Inc.","ticker":"CRVO","filing_date":"2026-08-10","form":"8-K","submitted_at":null,"items":[{"id":27711,"accession_number":"0001437749-26-026771","item_number":"2.02","item_title":"Results of Operations and Financial Condition","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"CervoMed issued a press release on August 10, 2026, announcing financial results for the quarter ended June 30, 2026, including cash position ($24.9 million), R\u0026D expenses ($4.3 million), G\u0026A expenses ($2.4 million), and net loss ($6.6 million). The filing explicitly states this is Item 2.02 disclosure with the press release attached as Exhibit 99.1, which is the standard format for earnings releases. The disclosure includes both financial results and material corporate updates (equity financings of $20.5 million, clinical trial progress, regulatory designations).","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T20:12:58.097483+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":27711,"accession_number":"0001437749-26-026771","item_number":"2.02","item_title":"Results of Operations and Financial Condition","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"CervoMed issued a press release on August 10, 2026, announcing financial results for the quarter ended June 30, 2026, including cash position ($24.9 million), R\u0026D expenses ($4.3 million), G\u0026A expenses ($2.4 million), and net loss ($6.6 million). The filing explicitly states this is Item 2.02 disclosure with the press release attached as Exhibit 99.1, which is the standard format for earnings releases. The disclosure includes both financial results and material corporate updates (equity financings of $20.5 million, clinical trial progress, regulatory designations).","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T20:12:58.097483+00:00","company_name":"CervoMed Inc.","ticker":"CRVO","filing_date":"2026-08-10"}]}